Literature DB >> 18466711

[Functional status of T helper cells in rheumatoid arthritis and effect of etanercept].

Ting-ting Lu1, Ping Zhu, Xiao-yan Li, Chun-mei Fan.   

Abstract

AIM: To ascertain the effect of etanercept treatment on the T-helper cells subsets (including Th1, Th2, Th17) in rheumatoid arthritis (RA).
METHODS: 20 RA patients and 10 age-matched healthy people were studied. The expression of IL-4, IFN-gamma and IL-17 on lymphocyte(CD4(+)) of RA patients peripheral blood were assessed by flow cytometry; Production of IFN-gamma, IL-4 and IL-17 were measured by enzyme-linked immunosorbent assay(ELISA)in RA sera pre- and post-12 weeks of therapy and that of 10 normal health controls were studied; correlations between percentage of IFN-gamma Th1, IL-17(+)Th17, value of Th1/Th2 and clinical factors were observed in RA.
RESULTS: The percentage of Th1 and Th17, intensity of Th17 and value of Th1/Th2 were higher than the healthy controls (P<0.05); After etanercept treatment the percentage and intensity of Th17 were significantly decreased (P<0.01), as well as the percentage of Th1 and value of Th1/Th2 (P<0.05), level of IL-17 decreased significantly but IFN-gamma, IL-4 had no significant difference; The percentage of IL-17(+)Th17 on CD4(+) T cells correlate positively to CRP and DAS28.
CONCLUSION: Th17 cells may play a role in the pathogenesis of RA, the down regulation of Th17 and Th1/Th2 is significant for the evaluation of the curative effect of etanercept.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18466711

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  2 in total

1.  Dysregulated ICOS+ proinflammatory and suppressive regulatory T cells in patients with rheumatoid arthritis.

Authors:  Hong-Xia Wang; Xia Kang; Shuai Chu; Haixia Li; Xin Li; Xiaofeng Yin; Yu-Rong Qiu; Weinan Lai
Journal:  Exp Ther Med       Date:  2018-08-24       Impact factor: 2.447

2.  The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.

Authors:  Balázs Szalay; Barna Vásárhelyi; Aron Cseh; Tivadar Tulassay; Magdolna Deák; László Kovács; Attila Balog
Journal:  Clin Rheumatol       Date:  2013-08-11       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.